QuidelOrtho Corp (QDEL) Q3 2026 Earnings Call Highlights: Revenue Falls 12% on China

QuidelOrtho Corp (QDEL) reported a 12% year-over-year revenue decline to $619 million in Q3 2026, driven by China destocking and softer respiratory testing. China revenue dropped 45% due to pricing changes and destocking, with further pressure expected. Adjusted gross margin contracted to 47.8%, and net leverage increased to 4.5 times EBITDA. The company plans cost savings and structural changes to offset headwinds and improve profitability.

Original reporting
Published Nov 4, 2026, 5:09 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 5:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
QuidelOrtho Corp (QDEL) Q3 2026 Earnings Call Highlights: Revenue Falls 12% on China — source image
Decision brief

The 30-second read

$QDELBearishHigh
01

Why it matters

The guidance cut and China revenue drop are likely to depress the stock in the short term, though the announced cost‑saving program may mitigate longer‑term risk.

02

Market read

The earnings miss and guidance reduction are material for QDEL and may influence sentiment across the diagnostic sector.

03

What to watch

The $80M annual savings program and restructuring charges may improve cash flow in 2027.

Relevance 8/10Novelty 8/10Timing: pre-market

Background

QuidelOrtho delivered its Q3 2026 earnings call, highlighting a revenue decline and revised guidance.

Company-level read

Ticker impact

$QDELBearishHigh confidence
Context

QDEL reported Q3 revenue down 12% to $619M and cut full-year revenue guidance to $2.52‑$2.54B.

Expected impact

likely pressure as the market prices in lower revenue and guidance.

Evidence & confidence

Guidance reduction and weak China sales are material; cost‑saving program will not offset until 2027.

Market effects

Diagnostic and IVD sector faces pricing pressure in China, potentially weighing peers.

US healthcare stocks may see modest pullback as investors reassess China exposure.

Signals broader concerns for global IVD manufacturers with China exposure.

Counterpoint

If China pricing stabilizes later, the cost‑saving program could boost margins and drive upside.

Key entities

  • Brian Blaser

    Provided commentary on operating model changes and China outlook.

  • Micah Young

    Outlined the $80M savings program and leverage metrics.

Related articles

$QDELMedAI 8/10

QuidelOrtho (QDEL) Q3 2026 Earnings Call Transcript

QuidelOrtho reported Q3 2026 revenue of $619M, down 12% YoY, with declines in Point of Care and China sales. Excluding China and respiratory, revenue rose 3%. The company announced a restructuring program to save $80M annually in 2027, focusing on cost cuts and business realignment. Management emphasized long-term growth strategies, including expanding the VITROS 450 and NULEXA platforms.

$QDELMedAI 8/10

What QuidelOrtho (QDEL) Said on Its Q3 Earnings Call

QuidelOrtho (QDEL) reported Q3 revenue decline, with Point of Care down 27% YoY. Management maintained a cautious outlook. The company announced a restructuring program targeting $80M in annual savings by 2027, with $30M-$35M in one-time charges in Q4. Adjusted EBITDA was $148M, and adjusted EPS was $0.31. QDEL narrowed its full-year revenue outlook to $2.52B-$2.54B and adjusted EBITDA to $540M-$545M.

$QDELHighAI 8/10

QuidelOrtho Q3 2026 slides: profit beat masks revenue challenges

QuidelOrtho (QDEL) reported Q3 2026 earnings of $0.31 per share, beating estimates, but revenue of $618.9M missed forecasts, causing a 6.62% after-hours drop. Revenue declined 12% YoY due to China's IVD pricing guidelines, with North America down 13.3% and China down 45.5%. Management narrowed full-year guidance, citing continued China pressure and cautious respiratory demand outlook. The company announced a restructuring plan to save $80M annually from 2027.

$QDELHighAI 8/10

QuidelOrtho: Q3 Earnings Snapshot

QuidelOrtho (QDEL) reported a Q3 loss of $53.8M, or 78 cents per share, with adjusted earnings of 31 cents per share. Revenue was $618.9M. The company expects full-year earnings of 65-70 cents per share and revenue of $2.52B-$2.54B, according to its Tuesday report.